OVERVIEW

Evolving Therapeutic Paradigms for the Management of Hyperkalemia is organized by Tarsus CNS.

Program Description:
Management of patients who are at chronic risk for hyperkalemia frequently include dietary modifications and/or discontinuation of specific medications that confer renal and/or cardiac protection. Weighing the risk of hyperkalemia against the risk of discontinuing reno- and cardio-protective therapies can present a paradox to clinicians treating hyperkalemia. Although the short-term management of hyperkalemia can be very effective, the utility of current strategies to manage hyperkalemia is limited, with no long-term outcome data to guide in the management of this condition. New therapies to manage hyperkalemia are currently available and under development that may provide safer, more consistent management.
This activity will review the most up-to-date clinical evidence on these new and potential therapies for the long-term management of hyperkalemia to improve guideline adherence and help clinicians move toward providing appropriate management for hyperkalemic patients with CKD, diabetes mellitus (DM), and/or HF by assessing risk profiles and customizing regimens based on individual patient needs.

Educational Objectives:
Upon completion of this activity, participants should be able to:
• Evaluate unmet needs in the treatment of hyperkalemia based on treatment guidelines, practice patterns, and available therapies.
• Discuss the benefits of novel agents that reduce risk of hyperkalemia in high-risk groups, such as CKD and HF.
• Elaborate on new clinical trial data regarding timing of drug ingestion and safety issues with novel agents that reduce serum potassium levels.
• Apply best practices for the treatment of hyperkalemia with potassium binding agents in patients with hyperkalemia based on clinical trial evidence and recent clinical experience.

Additional details will be posted as soon as they are available.

FACULTY

Joann Lindenfeld

Cardiovascular Disease, Internal Medicine

Robert Daniel Toto

MDNephrology, Internal Medicine

Rajiv Agarwal

MBBS, MD, MS, FASN, BRCUNephrology, Internal Medicine

SPECIALITIES

NephrologyCritical Care Medicine

CANCELLATION & REFUND POLICY

This is our canceling policy

Cancellations must be submitted in writing. If you are calling to cancel, for verification we will still require you to send an email to info@brainweek.org with your intent to cancel. You will receive confirmation of your cancellation via email.

We will offer a 100% refund within 72 hours from the time of purchase less $100 credit card processing fee.

After 72 hours, refunds will be less 50%. All refund requests must be made in writing and post marked or tax stamped no later than 90 days before the event.

No refund will be made if the request is made within 90 days of the educational event. Refunds will not be issued to non-show registrants.

Substitutions are always welcome in lieu of cancellation. No transfers to alternate events will be made if the request is submitted within 90 days of the original event.

Persons who register and fail to attend will not receive a refund. BRAINWeek, at its sole discretion, may transfer your registration to an upcoming conference or to a healthcare provider colleague. Cancellation of your conference registration does not automatically cancel your hotel room reservation. Please contact the hotel to cancel your room; penalties may apply.